ASH 2025: Sutacimig - A Novel Bispecific Antibody for Prophylactic Treatment of Glanzmann Thrombasthenia: Analysis of a Phase 2 Study
Presented at the ASH (American Society of Hematology) 2025 Annual Meeting and Exposition
To view the presentation, click here